OS Therapies (OSTX) Capital Expenditures (2025)

OS Therapies' (OSTX) quarterly Capital Expenditures came in at $316423.0 in Q2 2025, up 110.95% on a QoQ basis from $150000.0 in Q1 2025.

OS Therapies (OSTX) Capital Expenditures (2025) Analysis & Trends

OS Therapies (OSTX) has 1 years of Capital Expenditures data on file, last reported at $316423.0 in Q2 2025.

Quarterly Capital Expenditures changed N/A year-over-year to $316423.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $466423.0 (changed N/A YoY) and the FY2025 annual result came in at $466423.0, changed N/A from the prior year.
Capital Expenditures rose to $316423.0 in Q2 2025, from $150000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $316423.0 in Q2 2025 to a low of $150000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	OS Therapies	19.31 Mn	19.31 Mn	-	-

Download Data